These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27255136)

  • 61. Hemorrhagic stroke following use of the synthetic marijuana "spice".
    Rose DZ; Guerrero WR; Mokin MV; Gooch CL; Bozeman AC; Pearson JM; Burgin WS
    Neurology; 2015 Sep; 85(13):1177-9. PubMed ID: 26320200
    [No Abstract]   [Full Text] [Related]  

  • 62. ["Spice"--synthetic cannabinoids with dangerous effects].
    Personne M; Westerbergh J; Hammer-Pettersen L
    Lakartidningen; 2014 Nov; 111(47):2105-7. PubMed ID: 25386644
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synthetic cannabinoid use disorder: an update for general psychiatrists.
    Grigg J; Manning V; Arunogiri S; Lubman DI
    Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical and financial implications of emergency department visits for synthetic marijuana.
    Rowley E; Benson D; Tiffee A; Hockensmith A; Zeng H; Jones GN; Musso MW
    Am J Emerg Med; 2017 Oct; 35(10):1506-1509. PubMed ID: 28457767
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids.
    Wang GS; Buttorff C; Wilks A; Schwam D; Tung GJ; Banerji S; Dart RC; Pacula RL
    Am J Emerg Med; 2022 Mar; 53():150-153. PubMed ID: 35051702
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
    Goncalves R; Labadie M; Chouraqui S; Peyré A; Castaing N; Daveluy A; Molimard M
    Clin Toxicol (Phila); 2022 Apr; 60(4):458-463. PubMed ID: 34850659
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity.
    Worob A; Wenthur CJ
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016144
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spice/K2 drugs--more than innocent substitutes for marijuana.
    Zawilska JB; Wojcieszak J
    Int J Neuropsychopharmacol; 2014 Mar; 17(3):509-25. PubMed ID: 24169044
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
    Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
    Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthetic cannabinoid intoxication: a case series and review.
    Harris CR; Brown A
    J Emerg Med; 2013 Feb; 44(2):360-6. PubMed ID: 22989695
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recreational cannabinoid use: The hazards behind the "high".
    Wright S; Metts J
    J Fam Pract; 2016 Nov; 65(11):770-779. PubMed ID: 28087865
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
    Malaca S; Tini A; Umani Ronchi F
    Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions.
    Brown JD; Rivera Rivera KJ; Hernandez LYC; Doenges MR; Auchey I; Pham T; Goodin AJ
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S37-S52. PubMed ID: 34396558
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
    Macfarlane V; Christie G
    Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
    Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
    J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Potential Mechanisms Underlying Marijuana-Associated Periodontal Tissue Destruction.
    Scott DA; Dukka H; Saxena D
    J Dent Res; 2022 Feb; 101(2):133-142. PubMed ID: 34515556
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
    Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
    Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
    King A; Hill SL; Pucci M; Bailey G; Keating L; Macfarlane R; Cantle F; Hudson S; Thomas SHL
    Clin Toxicol (Phila); 2022 Oct; 60(10):1094-1098. PubMed ID: 35943421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.